Join
Live feed
·
INSIDERFilingvia Quantisnow
Entrada Therapeutics Inc. logo

President, Research & Develop. Sethuraman Natarajan sold $10,800 worth of shares (600 units at $18.00), decreasing direct ownership by 0.33% to 183,216 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
TRDA· Entrada Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TRDA (Entrada Therapeutics Inc.) and more on Quantisnow.